SCHEMBL2479796

SCHEMBL2479796

COc1cc(C(=O)/C(=C/N(C)C)CC2CCCCC2)c(OC)cc1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.43
KDM4E B2RXH2 2/20 0.43
HSD17B10 Q99714 2/20 0.43
MAPT P10636 1/20 0.43
TSHR P16473 1/20 0.43
PARP15 Q460N3 1/20 0.38
PARP10 Q53GL7 1/20 0.38
KMT2A Q03164 3/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
MEN1 O00255 2/20 0.38
HTT P42858 1/20 0.38
MCOLN3 Q8TDD5 1/20 0.38
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
PAX8 Q06710 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
ELANE P08246 1/20 0.35
AAK1 Q2M2I8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2479798 1.00 ALDH1A1 (0.43) ALDH1A1KDM4EHSD17B10MAPTTSHR
SCHEMBL2481869 0.89 ALDH1A1 (0.43) ALDH1A1KDM4EHSD17B10MAPTTSHR
SCHEMBL2481868 0.89 ALDH1A1 (0.43) ALDH1A1KDM4EHSD17B10MAPTTSHR
SCHEMBL2480716 0.88 TSHR (0.44) ALDH1A1KDM4EHSD17B10MAPTTSHR
SCHEMBL2477627 0.88 KDM4E (0.44) ALDH1A1KDM4EHSD17B10MAPTTSHR
SCHEMBL2477624 0.88 KDM4E (0.44) ALDH1A1KDM4EHSD17B10MAPTTSHR
SCHEMBL2480715 0.88 TSHR (0.44) ALDH1A1KDM4EHSD17B10MAPTTSHR
SCHEMBL2482136 0.72 NPC1 (0.50) ALDH1A1KDM4EHSD17B10KMT2AMEN1
SCHEMBL7682170 0.72 NPC1 (0.50) ALDH1A1KDM4EHSD17B10KMT2AMEN1
SCHEMBL2481231 0.71 NPC1 (0.48) ALDH1A1KDM4EHSD17B10TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2114408-B1 SUBSTITUTED AMINOPYRIMIDINES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS MERCK SHARP & DOHME (US) 2011-10-12 EP disclosed
US-20100113492-A1 Substituted Aminopyrimidines as Cholecystokinin-1 Receptor Modulators MERCK & CO., INC. (US) 2010-05-06 US disclosed
EP-2114408-A1 SUBSTITUTED AMINOPYRIMIDINES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS Merck & Co., Inc. (US) 2009-11-11 EP disclosed
WO-2008091631-A1 SUBSTITUTED AMINOPYRIMIDINES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS MERCK & CO., INC. (US) 2008-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113492-A1 Substituted Aminopyrimidines as Cholecystokinin-1 Receptor Modulators CCKAR, CCKBR, GLP1R ALDH1A1 4345/4885KDM4E 3052/4885HSD17B10 2464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.